Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR48692 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| SR48692 | DRUG | - |
Inclusion Criteria: * Pathological diagnosis: Histologically or cytologically proven SCLC. * Disease stage: extensive stage * Measurable disease by the RECIST criteria is required. Lesions that are present in previously irradiated area are non-measurable unless they have appeared or progressed sinc...
Top 20 of 76 competitors
SR48692, also known as meclinertant, is an investigational small molecule being studied for the treatment of lung cancer, specifically small cell lung cancer. It is being evaluated as a maintenance therapy following first-line chemotherapy with cisplatin plus etoposide.
SR48692 targets the neurotensin receptor, a G protein-coupled receptor involved in cancer cell proliferation and survival. By blocking this receptor, the drug aims to inhibit tumor growth and potentially improve outcomes in patients with small cell lung cancer.
SR48692 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the drug's safety and efficacy in patients with lung cancer.
SR48692 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind study evaluating overall survival compared to placebo in patients with small cell lung cancer after first-line chemotherapy.
SR48692 has been studied in one completed clinical trial, registered as NCT00290953. This Phase 2 trial enrolled 432 patients with small cell lung cancer across multiple countries, including the United States, France, Germany, and Japan, to assess overall survival.
Yes, SR48692 is also known as meclinertant. The drug is referred to by both names in clinical research and literature, with meclinertant being the international nonproprietary name and SR48692 being the investigational code.